Synagis 50mg/0.5ml Injection

Introduction of Synagis 50 mg/0.5 ml Injection

Synagis 50 mg/0.5 ml Injection is a prescription medicine containing Palivizumab, a monoclonal antibody used to prevent severe respiratory syncytial virus (RSV) infections in high-risk infants and young children. It provides passive immunity by targeting the RSV virus, helping reduce hospitalizations due to severe RSV infection.

Description of Synagis 50 mg/0.5 ml Injection

• Composition: Each 0.5 ml injection contains 50 mg of Palivizumab.

• Formulation: Injectable solution for intramuscular use.

• Therapeutic Class: Monoclonal antibody / RSV prophylaxis.

• Mechanism of Action: Palivizumab binds to RSV, preventing the virus from entering healthy cells. This helps protect high-risk infants, especially premature babies or those with certain heart or lung conditions, from severe RSV disease.

Benefits

• Prevents severe RSV infection in high-risk infants and children.

• Reduces the likelihood of hospitalization due to RSV.

• Helps protect children with premature birth, congenital heart disease, or chronic lung disease.

• Provides passive immunity during RSV season.

How to Use

• Administered intramuscularly by a healthcare professional.

• The usual dosage is 50 mg per 0.5 ml, typically given once a month during RSV season, as per doctor’s recommendation.

• The injection should be given according to medical guidelines for correct dose and safety.

• Monitor the child for any immediate reactions after administration.

Uses

• Prevention of severe RSV infection in:

  • Premature infants

  • Children with congenital heart disease

  • Children with chronic lung disease of prematurity

• Reduces risk of RSV-related hospitalization in high-risk pediatric patients.

Side Effects

Common side effects:

• Fever

• Rash

• Injection site reactions (redness, swelling, pain)

• Diarrhea

• Upper respiratory tract infection

Serious but rare side effects:

• Allergic reactions (swelling, itching, difficulty breathing)

• Severe injection site reactions (bruising, large swelling)

• Low blood pressure or rapid heart rate (rare)

⚠️ Safety Advice

• Only for use under healthcare supervision.

• Ensure proper monitoring during and after injection.

• Inform the doctor of any allergies, medical conditions, or medications before administration.

• Not recommended for children with known hypersensitivity to Palivizumab.

• Continue preventive measures such as hand hygiene and avoiding contact with sick individuals.